Current Status of Imatinib as Frontline Therapy for Chronic Myeloid Leukemia

Seminars in Hematology

Volumn 47, Issue 4, 2010, Pages 312-318

  Marin, David ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; GLYCOPROTEIN P; HYDROXYUREA; IMATINIB; ORGANIC CATION TRANSPORTER 1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG MONITORING; EDEMA; EVENT FREE SURVIVAL; FATIGUE; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; LONG TERM CARE; MOLECULAR CLONING; MOLECULAR EVOLUTION; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SAFETY; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL TIME; TERATOGENICITY; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROGNOSIS; PYRIMIDINES;

EID: 77957084918     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.06.003     Document Type: Article

References (51)

1. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003, 348:994-1004.
2. Druker B., Guilhot F., O'Brien S., et al. Five-year follow-up of imatinib therapy for newly diagnosed chronic myelogenous leukemia in chronic-phase shows sustained responses and high overall survival. N Engl J Med. 2006, 355:2408-2417.
3. Hochhaus A., O'Brien S.G., Guilhot F., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
4. Allan N.C., Richards S.M., Shepherd P.C. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995, 345:1392-1397.
5. Arora M., Weisdorf D.J., Spellman S.R., et al. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol. 2009, 27:1644-1652.
6. de Lavallade H., Apperley J.F., Khorashad J.S., et al. Imatinib for newly diagnosed patients with chronic myeloid leukaemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008, 26:3358-3363.
7. Bonifazi F., de Vivo A., Rosti G., et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001, 98:3074-3081.
8. Lin F., Chase A., Bungey J., Goldman J.M., Cross N.C. Correlation between the proportion of Philadelphia chromosome-positive metaphase cells and levels of BCR-ABL mRNA in chronic myeloid leukaemia. Genes Chromosomes Cancer 1995, 13:110-114.
9. Marin D., Milojkovic D., Olavarria E., et al. European LeukemiaNet criteria for failure or sub-optimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008, 112:4437-4444.
10. Baccarani M., Cortes J., Pane F., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009, 27:6041-6051.
11. Cortes J.E., Baccarani M., Guilhot F., et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010, 28:424-430.
12. Baccarani M., Rosti G., Castagnetti F., et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009, 113:4497-4504.
13. Hughes T.P., Kaeda J., Branford S., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003, 349:1423-1432.
14. Lucas C.M., Wang L., Austin G.M., et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008, 22:1963-1966.
15. Sokal J.E., Cox E.B., Baccarani M., et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984, 63:789-799.
16. Marin D., Marktel S., Bua M., et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia 2003, 17:1448-1453.
17. Milojkovic D., Nicholson E., Apperley J.F., et al. Early prediction of success or failure using second generation tyrosine kinase inhibitors for chronic myeloid leukemia. Haematologica 2010, 95:224-231.
18. Sokal J.E., Baccarani M., Tura S., et al. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood 1985, 66:1352-1357.
19. Marin D., Bazeos A., Mahon F.X., et al. Adherence is the critical factor for achieving molecular responses in chronic myeloid leukemia patients who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010, 28:2381-2388.
20. Thomas J., Wang L., Clark R.E., Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004, 104:3739-3745.
21. White D.L., Dang P., Engler J., et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2010, 28:2761-2767.
22. Milojkovic D., Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res. 2009, 15:7519-7527.
23. Dulucq S., Bouchet S., Turcq B., et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008, 112:2024-2027.
24. Radich J.P., Dai H., Mao M., et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006, 103:2794-2799.
25. Oehler V.G., Yeung K.Y., Choi Y.E., et al. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood 2009, 114:3292-3298.
26. Zhang W.W., Cortes J.E., Yao H., et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol. 2009, 27:3642-3649.
27. de Lavallade H., Finetti P., Carbuccia N., et al. A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia. Leuk Res. 2010, 34:254-257.
28. McWeeney S.K., Pemberton L.C., Loriaux M.M., et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood 2010, 115:315-325.
29. Yong A.S., Szydlo R.M., Goldman J.M., Apperley J.F., Melo J.V. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 2006, 107:205-212.
30. Quintas-Cardama A., Kantarjian H., Jones D., et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 2009, 113:6315-6321.
31. Kantarjian H.M., Talpaz M., O'Brien S., et al. Survival benefit with imatinib mesylate versus Interferon-α-based regimens in newly diagnosed chronic phase chronic myelogenous leukemia. Blood 2006, 108:1835-1840.
32. Tam C.S., Kantarjian H., Garcia-Manero G., et al. Failure to achieve a major cytogenetic response by twelve months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 2008, 112:516-518.
33. Picard S., Titier K., Etienne G., et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2006, 109:3496-3501.
34. Larson R.A., Druker B.J., Guilhot F., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111:4022-4028.
35. Kantarjian H.M., Shan J., Jones D., et al. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol 2009, 27:3659-3663.
36. Marin D., Khorashad J.S., Foroni L., et al. Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?. Br J Haematol 2009, 145:373-375.
37. Press R.D., Galderisi C., Yang R., et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 2007, 13:6136-6143.
38. Cross N.C., Hughes T.P., Hochhaus A., Goldman J.M. International standardisation of quantitative real-time RT-PCR for BCR-ABL. Leuk Res 2008, 32:505-506.
39. Kantarjian H.M., Dixon D., Keating M.J., et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988, 61:1441-1446.
40. Marktel S., Marin D., Foot N., et al. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica 2003, 88:260-267.
41. Vardiman J.W., Pierre R.V., Thiele J., et al. Chronic myelogenous leukaemia. World Health Organization classification of tumours. Tumours of haematopoietic and lymphoid tissues 2001, 20-26. IARC Press, Lyon, France. S.E. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (Eds.).
42. Faderl S., Talpaz M., Estrov Z., et al. The biology of chronic myeloid leukemia. N Engl J Med. 1999, 341:164-172.
43. Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
44. Shah N., Nicoll J., Nagar B., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-223.
45. Khorashad J., de Lavallade H., Apperley J., et al. The finding of kinase domain mutations in chronic phase CML patients responding to imatinib may identify those at high risk of disease progression. J Clin Oncol. 2008, 26:4806-4813.
46. Noens L., van Lierde M.A., De Bock R., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113:5401-5411.
47. Pye S.M., Cortes J., Ault P., et al. The effects of imatinib on pregnancy outcome. Blood 2008, 111:5505-5508.
48. Ault P., Kantarjian H., O'Brien S., et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 2006, 24:1204-1208.
49. Rousselot P., Huguet F., Rea D., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007, 109:58-60.
50. Cortes J.E., Jones D., O'Brien S., et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010, 28:392-397.
51. Cortes J.E., Jones D., O'Brien S., et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010, 28:398-404.